Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 11, 2018 09:15 ET | Source: Novan, Inc.

Novan Announces Closing of Offering of Common Stock and Warrants

MORRISVILLE, N.C., Jan. 11, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced that it has closed its previously announced underwritten public offering. ...
January 11, 2018 09:10 ET | Source: Novan, Inc.

Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference

MORRISVILLE, N.C., Jan. 11, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Phase 2 efficacy and safety data for SB208, a topical, silicone-based...
January 05, 2018 09:00 ET | Source: Novan, Inc.

Novan Announces Pricing of $38.0 Million Offering of Common Stock and Warrants

MORRISVILLE, N.C., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's underwritten offering of 10 million shares of...
January 04, 2018 16:07 ET | Source: Novan, Inc.

Novan Announces Proposed Public Offering of Common Stock and Warrants

MORRISVILLE, N.C., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it intends to offer and sell, subject to market and other conditions,...
December 05, 2017 08:35 ET | Source: Novan, Inc.

Novan Announces First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414

MORRISVILLE, N.C., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the first patient has been dosed in the Company's Phase 1b clinical...
November 22, 2017 08:25 ET | Source: Novan, Inc.

Novan to Present at Piper Jaffray 29th Annual Healthcare Conference

MORRISVILLE, N.C., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that Nathan Stasko, PhD, President and Chief Scientific Officer of Novan, is...
November 07, 2017 08:05 ET | Source: Novan, Inc.

Novan Announces Plan to Complete Development of SB204 Acne Candidate via Third Party Funding and Execution

MORRISVILLE, N.C., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that it has agreed in principle to a business structure that would enable...
October 18, 2017 07:05 ET | Source: Novan, Inc.

Novan Acquires IP Rights to Treat Viral Malignancies with Nitric Oxide

Expanded Indications in Field of Virology Build on SB206 Clinical Success Against Human Papillomavirus Company Doses First Patient in Inflammatory Skin Disease Program in Phase 1b Psoriasis Trial...
October 13, 2017 08:35 ET | Source: Novan, Inc.

Novan Announces Corporate Update Conference Call and Webcast

MORRISVILLE, N.C., Oct. 13, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Wednesday, October 18, at...
September 26, 2017 08:30 ET | Source: Novan, Inc.

Machelle Sanders Appointed to Novan Board of Directors

MORRISVILLE, N.C., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced the appointment of Machelle Sanders to the Company’s Board of Directors....